Create a priority-setting and decision making framework for expensive drugs for rare diseases.
- Home
- Our Team
- Emerging Research Cluster
- Research Units
- The Centre for Clinical Epidemiology & Evaluation (C2E2)
- The Centre for Health Evaluation and Outcome Sciences (CHÉOS)
- Centre of Genomics and Policy (CGP)
- Child & Family Research Institute (CFRI) – Genetics & Health Research
- Collaboration for Outcomes Research and Evaluation (CORE)
- Joint Centre for Bioethics (JCB)
- The Ontario Drug Policy Research Network (ODPRN)
- The Ottawa Hospital Research Institute (OHRI)
- Toronto Health Economics and Technology Assessment (THETA) Collaborative
- Current Projects
- Implementation of Diagnostic Whole Genome Sequencing for Rare Diseases in British Columbia
- GenCOUNSEL: Optimization of genetic counselling for clinical implementation of genome-wide sequencing
- MILLION DOLLAR MED$
- Clinical Assessment of the Utility of Sequencing and Evaluation as a Service (CAUSES)
- Engaging publics on reimbursement decision-making for expensive drugs for rare diseases
- Crowdfunding As a New Approach to Financing Orphan Drug R&D (CANAFORD)
- Informing Future Orphan Drug Coverage Using Scenario Studies (iFOCUSS)
- An Evaluation of Canadian Societal Values and Views on Funding and coverage of Expensive Prescription Medications
- Narrative Bioethics and Popular Conceptions of Genetic Disorder
- Resource Allocation for the Treatment of Rare Diseases
- News
- Career Opportunities
- Contact Us
CIHR New Emerging Team
